GLP-1 and incretin compared

Retatrutide vs semaglutide

An investigational triple agonist and an approved GLP-1 agonist, side by side.

Retatrutide is an investigational agonist of the GIP, GLP-1 and glucagon receptors, and semaglutide acts on the GLP-1 receptor.1,2,3 An early report gives retatrutide's half-life as approximately 6 days, and the Ozempic label gives semaglutide's as approximately 1 week.4,3

Semaglutide has been approved in the US since 2017, while the FDA says retatrutide is not a component of an FDA-approved drug.3,5 The weight figures below come from separate trials. A 2026 review, with evidence to 11 September 2026, reports no completed head-to-head trial of retatrutide and names TRANSCEND-T2D-2, against semaglutide in type 2 diabetes, as a randomised comparison that could support one.6,7

FactRetatrutideSemaglutide
What it isAn investigational agonist of the GIP, GLP-1 and glucagon receptors1,2A GLP-1 receptor agonist marketed by Novo Nordisk3
How it comesOnce-weekly subcutaneous injection in trials; not a component of an FDA-approved drug6,5Ozempic pens of 0.68, 1.34 or 2.68 mg/mL, injected under the skin once weekly3
Half-life
  • Approximately 6 days in an early report in people with diabetes4
  • 134 to 165 hours in the first-in-human study, per a recent review2
  • Approximately 1 week on the Ozempic label3
  • Approximately 1 week in the European product information10
Doses and results
  • Mid-stage trial, 338 adults: 1, 4, 8 or 12 mg once weekly; no dose is approved1,5
  • Late-stage trial, 2339 adults on 4, 9 or 12 mg or placebo: weight -17.6%, -23.7% and -25.0% at 80 weeks against -3.9% on placebo6
  • Ozempic label: 0.25 mg for 4 weeks, then 0.5, 1 or 2 mg once weekly3
  • Wegovy label: injection 1.7 or 2.4 mg once weekly, up to 7.2 mg; also comes as tablets11
  • Placebo-controlled trial, 1961 adults on 2.4 mg or placebo: weight -14.9% at 68 weeks against -2.4% on placebo7
StatusNot a component of an FDA-approved drug, and not approved by the TGA or a comparable international regulator5,9First approved in the US in 2017, as Ozempic; also approved as Wegovy3,11

Get the app

Contents5
  1. 1How they differ
  2. 2Logged in Milligram
  3. 3What is not known
  4. 4References
  5. 5Related pages

Last reviewed . Sources are listed below.

How they differ

Retatrutide adds the GIP and glucagon receptors to the GLP-1 receptor that semaglutide acts on, and in obese mice the authors report that weight loss was augmented by glucagon receptor-mediated increases in energy expenditure.8 A 2026 review states that improvement in blood sugar control supports the net efficacy of the combined molecule rather than a separately quantified benefit for each receptor.2

The weight figures in the table come from different trials: retatrutide's ran 80 weeks and was funded by Eli Lilly, and semaglutide's ran 68 weeks and was funded by Novo Nordisk.6,7

Logged in Milligram

  • Retatrutide: 49% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Semaglutide: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

A 2026 review states that retatrutide's indications, contraindications and prescribing instructions require regulatory review, and that rare events, pregnancy exposure and long-term effects need larger datasets and dedicated follow-up.2 The TGA states that any retatrutide product accessed outside of clinical trials could be a counterfeit product.9

In a boxed warning, the Ozempic label states that semaglutide causes thyroid C-cell tumors in rodents, that it is unknown whether Ozempic does in humans, and that Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.3

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Peer-reviewed paper (phase 2), 2023. PMID 37366315
  2. Mateescu DM, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Peer-reviewed narrative review, full text (evidence to 11 September 2026), 2026. PMC13708278
  3. Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label
  4. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Peer-reviewed paper (phase 1b), 2022. PMID 36354040
  5. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Regulator web page, 2026. fda.gov
  6. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Peer-reviewed paper (phase 3), 2026. PMID 42814954
  7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Journal article (PubMed), 2021. PMID 33567185
  8. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Peer-reviewed paper (preclinical and phase 1), 2022. PMID 35985340
  9. Therapeutic Goods Administration (Australia). TGA tests counterfeit retatrutide product following serious adverse event report. Regulator web page, 2026. tga.gov.au
  10. European Medicines Agency. Ozempic: summary of product characteristics (EPAR product information). EU product information, 2026. ema.europa.eu
  11. Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection and tablets. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label